Johns Hopkins ABX Guide
Rebyota
INDICATIONS
FDA
FDA
- Prevention of recurrent Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI
- Rebyota is NOT indicated for the treatment of CDI.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: September 10, 2023
Citation
Dzintars, Kathryn. "Rebyota." Johns Hopkins ABX Guide, The Johns Hopkins University, 2023. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540780/all/Rebyota.
Dzintars K. Rebyota. Johns Hopkins ABX Guide. The Johns Hopkins University; 2023. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540780/all/Rebyota. Accessed November 22, 2024.
Dzintars, K. (2023). Rebyota. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540780/all/Rebyota
Dzintars K. Rebyota [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2023. [cited 2024 November 22]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540780/all/Rebyota.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Rebyota
ID - 540780
A1 - Dzintars,Kathryn,Pharm.D., BCPS
Y1 - 2023/09/10/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540780/all/Rebyota
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
